<< Oral salmon calcitonin using absorption-enhancing Eligen Technology holds promise for osteoarthritis | Report on the Malaysian pharmaceuticals and healthcare industry >>

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

19. October 2009 07:58

Study to examine trabedersen vs. current standard chemotherapy in patients with recurrent or refractory anaplastic astrocytoma

The biopharmaceutical company Antisense Pharma GmbH has announced today that it has received the approval by Health Canada for its pivotal Phase III clinical trial SAPPHIRE in patients with recurrent or refractory anaplastic astrocytoma.

The SAPPHIRE study is a randomized, active-controlled, clinical trial designed to confirm the efficacy and safety of the investigational drug trabedersen (AP 12009), observed in previous clinical studies. Trabedersen is being investigated as monotherapy compared to current standard therapy with temozolomide (alternatively BCNU (carmustine)). The results of a previous randomized, active-controlled Phase IIb study show that the novel, targeted therapy holds significant promise. Currently recruiting study centers will be published on www.anticancer.de.

Source: ANTISENSE PHARMA GMBH

01a880a2-87a5-41db-978b-e94929238a29|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: Angiogenesis, Antisense, Brain, Brain Tumor, Cancer, Catheter, Chemotherapy, Colorectal Cancer, Glioblastoma, Glioma, Hospital, Life Expectancy, Melanoma, Metastasis, Oligonucleotides, Oncology, Pancreatic Cancer, Radiotherapy, Temozolomide

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activityPeregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatid...Findings may lead to new drug therapies to reduce breast cancer metastasisResearchers have reduced breast cancer metastasis to bone using an experimental agent to inhibit ROC...Issuance of patents for Idera Pharmaceuticals' TLR-targeted compounds announcedIdera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the issuance of patents covering its nove...Comprehensive analysis of statin drug marketReportlinker.com announces that a new market research report is available in its catalogue: Statins:...Panel Intelligence expands patient focused market research servicePanel Intelligence, LLC, is pleased to announce expanded capabilities for patient focused market res...Clothes for women who undergo a mastectomyOne in eight U.S. women will be diagnosed with breast cancer during their lifetime, and currently sl...New drug compound Salirasib brings hope to pancreatic cancer patientsEvery year, 42,000 Americans are diagnosed with pancreatic cancer. Few live very long, and less than...Report says 650,000 cancer deaths avoided between 1990 and 2005The American Cancer Society's annual cancer statistics report finds that 15 years of steady declines...Brain tumor treatment may increase number of cancer stem-like cellsA new study suggests that the standard treatment for a common brain tumor increases the aggressivene...Opportunities for the health system in a sick economyWith the interim report of the National Health and Hospitals Reform Commission published yesterday t...New anti-tumor gene called SARIResearchers from Virginia Commonwealth University have identified a new anti-tumor gene called SARI ...Novel device enhances efficacy of standard chemotherapyNovoCure Ltd. presented results yesterday evaluating the Novo-TTF device in vitro and in a pilot cli...Barr confirms patent challenge of TEMODARBarr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated...Women with chronic obstructive pulmonary disease fare worse than menWomen with chronic obstructive pulmonary disease (COPD) fare worse than men both in terms of the sev...Botox finds a use in cancer treatmentThe cosmetic treatment Botox may have a new use as an adjuvant to cancer therapy, providing an open ...Experts call for more research into treatments for children's brain tumoursMore independent study is needed into the biology of children's brain tumours if effective treatment...Walking can cut craving for a cigaretteNew research by scientists at Exeter University has shown that going for a walk can help smokers bre...Gene therapy shows effect in heart patientsThe first double-blind, placebo-controlled randomized trial of VEGF gene injections into the heart m...UK's NHS selects Health Language for IT healthcare solutionHealth Language, Inc., (HLI) the world's leading supplier of medical vocabulary and concept-based te...

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Add comment

Quirky Comment Title
Name*
E-mail* (Will show your Gravatar icon)
Country Country flag

b i u quote

Comment
Preview

Notify me when new comments are added

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.

Free!

Recent Comments

Twitter

Information

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

Recent Articles

Free!

Recent Comments

Twitter

Information

Antisense Pharma's SAPPHIRE Phase III trial evaluating trabedersen approved by Health Canada

Medical News Cloud

Recent Articles